Clinical trials: Chronic Hepatitis C Virus Infection
Hepatitis C
A Study of Chronic Hepatitis C Patients Treated With SOF/VEL/VOX
This is a retrospective, non-interventional study. Investigators from infectious diseases and gastroenterology departments will participate this study. Patients data will be collected from hospital medical records.
- Trial name
- VOSEVI_Reg (NCT06010524)
- Where
- Turkey (Türkiye)
- Volunteers
- 450 people
- Sponsor
- Cerrahpasa Medical Faculty Foundation
Hepatitis C
Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine
50-60% of patients with chronic hepatitis C are not cured by treatment with pegylated IFNα plus ribavirin. Retreatment of non-responders of previous (pegylated) IFNα plus ribavirin therapies with pegylated IFNα plus ribavirin…
- Trial name
- NCT00310336
- Testing
- S-adenosyl-L-methionine, betaine, pegylated interferon alpha2b
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Basel, Switzerland
Chronic Hepatitis C
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
This study will evaluate the safety, tolerability, and efficacy of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C infection who have failed to eradicate hepatitis C despite previous…
- Trial name
- RESOLVE (NCT02745535)
- Testing
- Sofosbuvir/Velpatasvir/Voxilaprevir
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Maryland, Baltimore
Hepatitis C Virus
The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
This study seeks to assess the durability of response and persistence of resistance to ombitasvir/ paritaprevir/ritonavir in Japanese participants who enrolled in a Phase 2 or 3 clinical study with these agents for the treatment…
- Trial name
- NCT02581020
- Where
- 53 sites in Japan
- Volunteers
- 344 people
- Sponsor
- AbbVie
Psychiatric Disorders, Cognitive Impairment
Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related
Chronic hepatitis HCV-related is the most common cause of chronic liver disease in Italy. Patients with chronic hepatitis C present a prevalence of depressive disorders higher than that of the general population; moreover, it has…
- Conditions
- Psychiatric Disorders, Cognitive Impairment, Chronic Hepatitis c
- Trial name
- NCT03313154
- Testing
- Neuropsychiatric screening
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliero Universitaria di Cagliari
Hepatitis C, Chronic
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection
This multi-center, prospective observational study will evaluate the correlation of liver biopsy and transient elastography in liver fibrosis assessment in patients with chronic hepatitis C. Data will be collected for 96 weeks.
- Trial name
- NCT01671046
- Where
- 10 sites in Brazil
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic, DIABETES MELLITUS Type 2
The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients
The purpose of this study is to investigate if nitazoxanide used in combination with interferon alfa and ribavirin is effective in treating Hepatitis c infected type 2 Diabetic patients by improving their sustained viral response…
- Trial name
- HEP-C-FM (NCT01770483)
- Testing
- nitazoxanide, conventional interferon alfa, Ribavirin
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Viral Hepatitis C
SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF
This study will follow a group of people with chronic hepatitis C infection of genotype 3 who have mild to moderate liver fibrosis (stages F0-F2, measured by a liver stiffness test).
- Trial name
- NCT07316842
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Center of target therapy
Chronic Hepatitis C
PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)
This study aim to evaluate the non-inferiority of sustained virologic response in peginterferon alfa-2a and weight-based ribavirin for 16 weeks compare with standard treatment duration of 24 weeks in patients who achieved rapid…
- Trial name
- NCT01056172
- Testing
- Peginterferon alfa-2a and Ribavirin
- Where
- 8 sites in South Korea
- Volunteers
- 164 people
- Sponsor
- Pusan National University Yangsan Hospital
Hepatitis C
Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection
To evaluate the efficacy and safety of direct acting anti-viral agents (DAA) therapy in chronically infected Hepatitis C Virus (HCV) patients using an individualized response guided therapy (RGT) model.
- Trial name
- NCT03603327
- Testing
- Direct acting anti-viral agents
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Soroka University Medical Center
Chronic Hepatitis C, Chronic Hepatitis B
The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study
This study aims to demonstrate that patients with chronic hepatitis C (CHC) and B (CHB) experiencing regression of liver cirrhosis after effective antiviral therapy have decreased risk for hepatocellular carcinoma (HCC).
- Trial name
- ROLFH (NCT01831037)
- Testing
- Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
- Where
- 4 sites in United States, Canada
- Sponsor
- University of Arkansas
Hepatitis C, Chronic
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.
- Trial name
- NCT00375661
- Testing
- interferon-alfa-2b and ribavirin
- Where
- 2 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Kyoto University
Hepatitis C, Chronic
An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients
This prospective, national, multicenter, non-interventional study examined the use of triple combination therapy with boceprevir, pegylated interferon (peginterferon) alfa-2a and ribavirin in re-treating participants with…
- Trial name
- NCT02118597
- Testing
- Boceprevir, Simeprevir, Pegylated Interferon (Peginterferon) Alfa-2a
- Where
- 7 sites in Hungary
- Volunteers
- 19 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy
The purpose of this study is to determine the effectiveness of silymarin 700 mg thrice daily and assess the safety in patients with hepatitis C virus infection compared to a placebo.
- Trial name
- NCT01258686
- Testing
- Silymarin
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Bukwang Pharmaceutical
Chronic Hepatitis c
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
- Trial name
- NCT03673696
- Testing
- HEC74647PA Capsule
- Where
- China
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Hepatitis C
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
This multicenter study was to evaluate subjects with chronic genotype 2 or 3 HCV infection who were interferon (IFN) ineligible, IFN intolerant or unwilling to take IFN.
- Trial name
- POSITRON (NCT01542788)
- Testing
- SOF, RBV
- Where
- 63 sites in United States, Australia and 3 more
- Volunteers
- 278 people
- Sponsor
- Gilead Sciences
Hepatitis C, Hepatitis C, Chronic
Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin
Chronic hepatitis C infection is one of the leading causes of chronic liver disease in the United States. Approximately one-third of patients with hepatitis C infection develop cirrhosis of the liver, which can lead to liver…
- Trial name
- NCT00039962
- Testing
- thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- SciClone Pharmaceuticals
Chronic Hepatitis C, Cirrhosis
Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)
Since the availability of interferon free direct acting antivirals (DAA) the centers authorized to prescribed these drugs in Austria submitted their data to a central data base (AURIC) using treatment regimes without interferon…
- Trial name
- AURIC (NCT02628717)
- Where
- Austria
- Volunteers
- 558 people
- Sponsor
- Medical University of Vienna
Chronic Hepatitis C Infection
Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
This study is to assess the safety and tolerability of sofosbuvir (SOF) 400 mg with and without ribavirin (RBV) and/or with and without pegylated interferon alfa-2a (PEG) in subjects with genotype 1, 2 or 3 hepatitis C (HCV)…
- Trial name
- NCT01260350
- Testing
- SOF, RBV, PEG
- Where
- 2 sites in New Zealand
- Volunteers
- 292 people
- Sponsor
- Gilead Sciences
Hepatitis C
Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C
The purpose of the study is to investigate how the liver is affected with regard to inflammation and fibrosis during Sofosbuvir based treatment regimes of chronic hepatitis C.
- Trial name
- NCT02528461
- Testing
- Galactose, Gastroscopy, Liver biopsy
- Where
- Denmark
- Volunteers
- 71 people
- Sponsor
- University of Aarhus